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Abstract
The work contained in this thesis introduces a protein known as STING, an acronym for
STimulator of INnterferon Genes, an immunosurveillance ER-membrane bound adapter protein
critical to regulating the innate immune response in humans. The first chapter provides an
overview of the STING pathway, outlines STING’s potential as a therapeutic target of interest,
and delineates the primary challenges researchers encounter when designing small molecules
to modulate the activity of STING. Current efforts in developing STING modulators have
focused on devising agonists to up-regulate the STING pathway as a possible therapeutic for
human cancers based on the chemical scaffold of STING’s native ligand, 2’,3’-cGAMP, a cyclic
dinucleotide (CDN).
However, previous research has presented modest benefits and limited practical use for
their efforts. As a result, the second chapter presents a simple computational modeling protocol
termed site-restricted docking that can be incorporated into existing computational workflows to
screen vast libraries of monomeric chemical compounds in identifying potential STING
activators or inhibitors.
Furthermore, the third and final chapter outlines the modeling campaign devised to
screen potential STING modulators and illustrates the importance protein conformation has on
STING modulation.
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Chapter 1
Stimulator of Interferon Genes (STING): The Target of Interest

1.1 STING: An Introduction
The overall purpose of an organism’s immune system is to engage in a biochemical
arms race with deleterious agents by developing methods and techniques to recognize, identify,
and eliminate potential foreign invaders, diseased states, and instances where abnormal cellular
growth is unsustainable.
The first defense measure in humans is in activating and amplifying a robust innate
immune response that begins with the organism recognizing foreign (pathogen-associated
(PAMPs)) or self molecular patterns (damage-associated (DAMPs)) by pattern recognition
receptors (PRRs). Once identified, a downstream response activates the innate arm's initial
phase of human immunity, producing various cytokines and chemokines that activate different
macromolecular agents and biochemical pathways.1 The downstream mechanism(s) set in
motion by PRRs are complex signaling cascades to attenuate threats these agents pose to an
organism’s survival by manufacturing pro-inflammatory cytokines and type I interferons that
energize an organism’s natural immunity.1 One such PPR is a cytosolic DNA sensor known as
cyclic GMP-AMP synthase (cGAS), an enzyme extensively studied as an agent recognizing
foreign (bacterial, viral, fungal) or self nucleic acids (nucleic and mitochondrial).2
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Foreign or self-DNA recognized by cytosolic cGAS interacts with its c-terminal domain
containing a nucleotidyltransferase site (i.e., the catalytic part of the cGAS enzyme) that binds
negatively charged DNA via the sugar-phosphate backbone in a 2:2 stoichiometric ratio, the
minimal cGAS enzymatic unit.28 Upon DNA binding, the ligands induce conformational changes
within the protein that rearrange its catalytic pocket to accommodate the binding of two specific
nucleotides, guanosine monophosphate (GMP) and adenosine monophosphate (AMP).28 When
these nucleotides bind to cGAS, the protein endogenously generates a secondary messenger
known as cyclic GMP-AMP (cGAMP), a cyclic dinucleotide (CDN) and native ligand to the
endoplasmic reticulum (ER)-bound immune signaling protein known as STING, an acronym for
STimulator of INterferon Genes (also known as MITA, MPYS, ERIS, and TMEM173).3
Detection of PAMPs and DAMPs by the cGAS-STING pathway occurs within the cell’s
cytosol and is principally expressed in human cell lines that form a hub for immunosurveillance,
including the spleen, thymus, heart, lungs, and placenta, but are less commonly expressed in
other cell lines (e.g., the small intestines, liver, colon, brain, kidney, and skeletal muscle).3
As a natural immune adapter protein, STING identifies CDNs within the cytosol and,
upon binding, activates a downstream signal cascade that culminates in the activation of
interferon regulatory factor 3 (IRF3) genes that produce type I interferons (both interferon-α
(IFN-α) and interferon-β (IFN-β)) to elicit a pro-immune response.3 STING also produces
cytokines and chemokines via the nuclear factor-κB (NF-κB) pathway, which induces an
additional pro-inflammatory response.3 Consequently, STING serves as a molecular immune
checkpoint and, if under or over-activated, serves as a forerunner to many human disease
manifestations (e.g., cancers, autoimmunity, and autoinflammatory diseases).
As a result, STING is a critical and multifaceted target for scientific researchers, from
immune activation to regulating harmful conditions. Accordingly, the purpose of this introduction
is to provide the reader with a substantive overview of the STING pathway by summarizing
STING’s potential as a therapeutic target, offering a synopsis of the current outlook on the
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development of STING activators and inhibitors as well as explaining the current challenges
investigators face in generating potential STING modulators.

1.2 The STING Pathway
As mentioned earlier, STING is an innate immune adapter protein anchored to the cell’s
endoplasmic reticulum (ER) by four transmembrane domains (TM1-4) located near the protein’s
N-terminal region (Figure 1.1).1, 4 When sensing; STING can directly recognize CDNs produced
from bacteria that are composed of 3’-5’ phosphodiester linkages; examples include cyclic-diAMP (CDA), cyclic-di-GMP (CDG), and 3’,3’-cyclic-GMP-AMP (3’,3’-cGAMP).1 However, when
CDNs are assembled via human cGAS activation, the production of a secondary messenger
known as cyclic-GMP-AMP (cGAMP) contains the less conventional 2’-5’ and 3’-5’
phosphodiester linkages, i.e., 2’,3’-cGAMP, to commence STING activation.1
STING’s ligand-binding domain is generated by two STING monomers intertwining
(Figure 1.2) to bind CDNs and promotes the oligomerization and translocation of STING to the
Golgi for further processing.1, 28 A Cyro-EM structure of human STING (hSTING) in the apo state
(Figure 1.2) demonstrates the structural challenges researchers face in developing small
molecules to bind and activate STING, as the large and expansive protein contains a ligandbinding domain (LBD) estimated to be 952 cubic angströms, where tight dimerization is crucial
to substantive downstream signaling exemplified by the cross-promotion a bound ligand must
induce to rotate STING’s LBD 180° relative to its transmembrane region, thus allowing for high
order STING oligomers to form and amplify the activation of natural immune pathways in
humans.8, 48
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Figure 1.1. Cryo-EM structure of full-length apo-hSTING (R232) side view. PDB: 6NT5 at a resolution of 4.1 Å.8 Monomer A in blue and
Monomer B in green. (A) Illustrates the protein ribbon structure with annotations of specific structural components, and (B) overlays the STING
protein surface onto the STING ribbon structure.
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Figure 1.2. Cryo-EM structure of full-length apo-hSTING (R232) front view. PDB: 6NT5 at a resolution of 4.1 Å.8 Monomer A shown in blue and
Monomer B is shown in green. (A) illustrates the protein ribbon structure with annotations of specific structural components, and (B) overlays the
STING protein surface onto the STING ribbon structure.
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The literature hypothesizes that high-order STING oligomers partly form due to
conformational changes associated with a connector loop region on the side of a newly formed
STING dimer that shields highly conserved cystine-148 residues.9 Located in the
transmembrane’s fifteen amino acid (aa) linker region, cystine-148 is protected from a reducing
environment due to a side-by-side packing mechanism when multiple STING dimers interact,
allowing neighboring cysteine-148 residues to form disulfide bridges connecting adjacent STING
dimers that may increase the stability of nascent STING polymers.9
As a prerequisite for downstream signaling, STING must be trafficked from the ER to the
Golgi via an ER-Golgi intermediate compartment (ERGIC), a mechanism still unresolved,28 but
upon arrival at the Golgi coincides with the release of STING’s c-terminal tails (CTT) leading to
STING polymerization.1 Subsequent binding of tank-binding kinase 1 (TBK1), recruited by the
newly freed and highly conserved CTTs phosphorylate TBK1.1 Once phosphorylated; STING’s
CTTs then mobilize the recruitment of interferon regulatory factor 3 (IRF3) to the complex,
where IRF3 is phosphorylated by TBK1.1
The resulting phosphorylated IRF3 dimer ultimately translocates and enters the nucleus,
activating transcription genes related to the production of interferons (IFN) and inflammatory
cytokines.1 An important point to mention is that STING’s activity requires tight regulation given
the multitude of other upstream DNA sensors, other than cGAS, that can activate STING (e.g.,
Dead box polypeptide 41 (DDX41), IFN-γ-inducible protein 16 (IFI116), and DNA-dependent
activator of interferon regulatory factors (DAI)) by sensing foreign or self DNA in the cytosol.1 As
a result, the regulation of STING can be controlled through different post-translational
modifications to maintain innate immune homeostasis; examples include STING’s LBD for
phosphorylation132 and dephosphorylation133 and areas of STING’s transmembrane region for
ubiquitination22, 23, 24, 134 and palmitoylation1, 25.
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1.3 STING and Human Disease
The groundbreaking work for establishing a correlation between the activation of the ERbound STING and type I interferon production within the literature began with the study of
STING-knockout or STING-deficient mice, where an absence of functional or sufficient levels of
STING protein heightened mice’s susceptibility to infection by PAMPs.4-6 Shortly after that,
Russell Vance et al. discovered a bacterially produced CDN named cyclic diguanylate
monophosphate (c-di-GMP) that prompted an immune response initiated by STING.10
Although, it wasn’t until the discovery of Chen et al. in 2013 that revealed a critical
missing segment within the STING pathway, the identification of an enzyme named cyclic GMPAMP synthase (cGAS).11 Discussed earlier, cGAS is a cytosolic DNA sensor that can bind DNA
indiscriminate from its source, whether bacterial, viral, or self.1 2’ 3’-cGAMP, a CDN
endogenously produced by cGAS, binds and oligomerizes hSTING dimers to launch an immune
response.11 As a side note, human immunity's innate and adaptive arms operate synergistically
when establishing a reply. The natural branch of human immunity is essential in selecting,
extracting, and expressing antigens required for the adaptive component to prepare and initiate
a precise and pathogen-specific response.7
Ishikawa et al. demonstrated STING’s critical role in facilitating the activation and
development of cytotoxic T-cells when STING-deficient mice were administered a vaccine
containing a DNA plasmid that disseminated the ovalbumin protein.5 Therefore, it stands to
reason that STING impairment (hyperactivation, chronic activation, deactivation, etc.) could
result in potentially dire consequences for the health of a living organism. In addition, it's
essential to note that STING’s role is broad by producing type I IFNs and a range of proinflammatory cytokines and chemokines that provide vast potential for targeting infectious
diseases, including the herpes simplex virus 1 (HSV1) and retroviruses.1
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1.3.1 Autoimmune and Autoinflammatory Diseases
Moreover, given that all DNA contained within human cells and tissues has the potential
to prompt an inflammatory/immune response by STING, the protein has undergone appreciated
interest as a therapeutic target in treating autoimmune and autoinflammatory diseases.1 Various
autoimmune and autoinflammatory diseases such as ataxia-telangiectasia (AT), AicardiGoutières syndrome (AGS), STING-associated vasculopathy with onset in infancy (SAVI),
systemic lupus erythematosus (SLE), as well as, senescence-associated secretory phenotype
(SASP) which manifest due to hyper or chronic activation of the STING pathway.1
Spotlighting these syndromes shows the need to develop selective and potent
pharmaceutical interventions that can negatively impact STING oligomerization in situations
where hyper and chronic activation induces autoinflammatory, autoimmune, and senescenceassociated diseases.1

1.3.2 Cancer
Furthermore, as understanding STING’s functional capacity in adaptive immunity grows,
so does interest in developing STING activators. Persuasive evidence showing STING’s
assistance in antitumor immunity stems from the intratumoral injection of CDNs and CDN
analogs within skin,12 breast,13 colon,14 brain,15 pancreatic,16 and malignant B cell tumors17
which taken in totality demonstrates promising results STING agonists may have in reducing
tumor volume and increasing murine survival rates within the mouse models these research
studies investigated.
The following sections will describe the main STING variants present in the human
population, the basic structure of hSTING, and selective STING modulators previously
investigated that illustrate how STING activation depends on a protein-specific conformation of
the ligand-STING complex when developing novel STING modulators.
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1.4 The Human Variants of STING
A 379 amino acid residue protein encoded by the TMEM173 gene, STING is
characterized by five main variants in humans with varying magnitudes of instigating
downstream IFN signaling.1 Table 1 tabulates the information from the five main STING variants
and their relationship, if any, to a disease state in humans.
When analyzing single nucleotide polymorphisms (SNPs) from genotypic data of the
TMEM gene, five distinct STING variants emerged, the R232 (WT), R71H-G230A-R293Q
(HAQ), R232H (REF), G230A-R293Q (AQ), and R293Q (Q) variants respectively. The R232
allele, with a 57.9% population occurrence in humans, is the most common and is known in the
scientific literature as the wild-type (WT) variant; the R71H-G230A-R293Q polymorphic
sequence follows this at 20.4%, termed the HAQ variant, the R232H allele at 13.7% termed the
reference variant as it was the first STING variant discovered, as well as the G230A-R293Q
(AQ) allele at 5.2%, and finally the R293Q (Q) allele at 1.5% as the five main STING variants
observed in the human population.1
Although the R293Q substitution (Q variant) is not located in the STING ligand-binding
domain and thus does not come into direct contact with a potential ligand, the mutation occurs
on a surface groove of the STING protein and may negatively impact the binding of CDNs
containing 3’-5’ phosphodiester linkages, e.g., CDG.1 However when paired with a G230A
substitution at the 230 position within the LBD, i.e., the AQ variant, may assist in restoring some
hSTING signaling due to the decreased entropy at the 230 amino acid position resulting from a
glycine to alanine amino acid substitution.18
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Table 1. Determined Human STING (hSTING) Variants
Allelic
Allele Occurrence

Residue Position

Protein Motif

-

-

Relation to Immune Signaling
Designated the wild-type (WT) variant

References

WT

57.9%

HAQ

20.4%

REF

13.7%

R232H

β2-β3 loop connector

Lessening sensitivity to bacterial CDNs

13, 18

AQ

5.2%

G230A-R293Q

β2-β3 loop connector / α4

Lessening sensitivity to bacterial CDNs

13, 18-19

Q

1.5%

R293Q

α4

Decline of IFN-β activity to bacterial CDNs

13, 18-20

R71H-G230A-R293Q TM2-TM3 linker / β2-β3 loop connector / α4 Deemed the “loss-of-function” variant
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13, 18

13, 18-20

The R232H polymorphism with an approximate occurrence of 13.7% within the human
population potentially impairs or lessens the binding of ligands to STING’s LBD due to a single
R232H substitution that potentially increases lid region flexibility and destabilization of any
resulting STING oligomers.1 At the same time, the HAQ variant contains mutations inside and
outside the ligand-binding domain thought to substantially affect STING expression and CDN
binding to the STINGHAQ variant.1 Termed the loss-of-function STING allele; the HAQ variant
potentially suppresses nearly 90% of STING’s ability to generate an IFN response to all CDNs
when transfected into 293T cells.19
Additionally, In a variety of cell lines that expressed the homologous STINGHAQ variant,
e.g., in human B cells, lymphocytes, monocytes, and the peripheral blood mononuclear cells
(PBMCs) of mice where the HAQ allele was knocked-in, lowered the yield of expressed protein
as compared to the R232 (WT) allele and a diminished CDN response followed.20 Moreover,
carriers of the HAQ variant may be susceptible to attenuated antibacterial immune responses,
as suggested by a study that examined the HAQ variant's susceptibility in responding to
Legionnaire’s diseases contracted in humans.21
Collectively the data suggest that targeting the HAQ variant for modulation via small
molecules will be challenging, especially for individuals homozygous for the HAQ allele.20

1.5 Structural Analysis of hSTING Variants
The STING protein contains three essential elements a transmembrane (TM) region
connecting the protein to the ER (aa 1-140), a connector region (aa. 141-156), and a c-terminal
domain (CTD) comprised of a ligand-binding domain (LBD) (aa. 157-339) and cytosolic cterminal tails (CTT) (aa. 340-379) (Figure 1).22-26
STING, in its biologically relevant form, exists as two corresponding monomers that
adopt a “butterfly” conformation when bound to 2’,3’-cGAMP, as the apo conformation visually
resembles a pair of “wings” that are linked by a deep cleft created where STING dimerization
occurs (residues 153-180).1
11

An additional therapeutic site contained within the aa. 70-91 region, exposed to the
cytoplasm between the second and third transmembrane regions (TM2 and TM3), includes two
cysteines residing at positions 88 and 91, respectively, serving as sites for palmitoylation25 that
traffic STING from the ER to the Golgi for further downstream signal processing.28 Regions
within STING’s transmembrane region provide a different target from the LBD for therapeutic
intervention with the discovery of an indole urea compound, H-151, an experimentally
determined active compound against hSTING by covalently binding to cysteine 91, preventing
full palmitoylation of hSTING and its subsequent trafficking to the Golgi28 demonstrates STING
modulation can occur at various locations throughout the entire length of the STING protein.

1.6 Activation by Cyclic DiNucelotides
Five crystal structures of hSTING co-crystallized with CDG have been independently
determined in isolation by five different laboratories that seek to outline the mechanism by which
CDNs are sensed (PDBs 4EF4,27 4F9G,29 4F5Y,30 4EMT,31 and 4F5D32). The five STING crystal
structures adopt a “U-shaped” conformation when bound to CDG and exist either in an open
(inactive/partially active) or closed (fully operational) conformation of STING. However, only one
of these five crystal structures is of the closed CDG-STING conformation, 4F5D, a STINGHAQ
allele.27, 29-32 Once the endogenous secondary messenger 2',3'-cGAMP was discovered,33-36
crystal structures containing 2',3'-cGAMP-STING complexes of hSTING (PDB: 4KSY36 and
4LOH37) were determined of the R232 allele (4KSY) and R232H allele (4LOH) respectively.
When examining the 4KSY and 4LOH complexes, researchers noted their similarity to
the CDG-STING conformation 4F5D.1 Observing these two STING complexes suggested the
two monomers approached each other in a “V-shaped” conformation when CDNs were bound,
inducing distances between 34-38Å in the space separating STING monomers (Figures 2-4)
and was accompanied by the formation of an antiparallel four-stranded β-sheet (aa. 219-249
from each STING monomer), termed the “lid,” that researchers observed entirely encompassed
the native ligand 2’,3’-cGAMP in the STING binding pocket.1
12

Figure 2. X-ray structure of c-terminal domain apo-hSTING (R232H). PDB: 4EMU at a resolution of 1.90 Å depicting the front view.31 The alpha
1 and 2 helices are colored blue, and the lid region of each monomer is colored light green. Residues tyrosine-167, histidine-185, arginine-238,
and glutamine-266 are represented as thick tubes provided for clarity.
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Figure 3. X-ray structure of c-terminal domain c-di-GMP-hSTING (R232H). PDB: 4EMT at a resolution of 1.50 Å depicting the front view.31 The
alpha 1 and 2 helices are colored blue, and the lid region of each monomer is colored light green. Residues tyrosine-167, histidine-185,
arginine-238, and glutamine-266 are represented as thick tubes provided for clarity.
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Figure 4. X-ray structure of c-terminal domain 2’,3’-cGAMP-hSTING (R232H). PDB: 4LOH at a resolution of 2.25 Å depicting the front view.37
The alpha 1 and 2 helices are colored blue, and the lid region of each monomer is colored light green. Residues tyrosine-167, histidine-185,
arginine-238, and glutamine-266 are represented as thick tubes provided for clarity.
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Crystallographic evidence further elucidated 2’,3’-cGAMP to be uniquely suited to bind to
R232-STING, as the ligand is secured to the LBD by generating a network of polar and
hydrophobic interactions. For example, hydrogen bonding of a free 3’-OH group on the GMP
side of the compound to serine-162 located in the deep cleft of the binding pocket, paired with
pi-pi stacking interactions formed between the purine rings of both AMP and GMP to a
tyrosine-167 residue present on each STING monomer provides structural evidence that
dimerization occurs upon binding of 2’,3’-cGAMP.1
Further dimerization and closure of the lid region of STING are supported by the
interactions 2’,3’-cGAMP makes with arginines-232 and -238, located in the lid region, via
electrostatic interactions with the α-phosphate groups of 2’,3’-cGAMP, as well as the adenine
base’s interfacing directly with valine-239 in the lid region and its guanine base directly
interfacing with side chains glutamate-260 and threonine-263 within the dimerization region.1
By direct contrast, R232H-STING exhibits interactions with the guanine base of 2’,3’cGAMP in the dimerization region by coordinating with water-mediated hydrogen bonds in the
solvent expose pocket.1 Moreover, the adenine base is sequestered from interacting with the
hydrogen bonding network of the binding pocket.1 Taken together, the lid region of R232 may be
closer to 2’,3’-cGAMP when bound to the R232 allele versus the R232H polymorphism.1 The
connection between CDN-STING binding and how signal transduction propagates had been
largely unresolved until full-length versions of STING and polymers of STING were structurally
determined.8, 9, 38
Examining the structural analysis of the TBK1 dimer, which binds to STING during signal
transduction, suggests the presence of two kinase domains located in opposite positions, which
are antithetical to cis-autophosphorylation, indicating that higher-order STING oligomers are
constructed via trans-autophosphorylation due to the spatial position of serine-366 on STING’s
c-terminal tail, the site of STING phosphorylation, which is distance constrained from reaching
the bound TBK1’s kinase domain for phosphorylation,39 proposing the idea that TBK1
phosphorylation requires the cooperation of adjacent STING dimers.38 Therefore, STING
16

oligomerization is an essential signaling operation for the downstream complexing of TBK1 and
IRF3 via the process outlined in the previous section (Section 1.2).
Furthermore, CDG exhibits weaker binding affinity to STING than 2’,3’-cGAMP by not
inducing the valuable conformational changes that result in a compact active site showcased in
2’,3’-cGAMP-STING complexes of the wild-type and reference alleles.1 By comparison, the
resulting ligand-STING complex induced by CDG is quite similar to its apo structure (inactive
state) as a slightly compact form when compared seems to prompt the oligomerization of
STING. Still, it stands to reason that the less compact CDG-STING conformation may not be as
effective at binding TBK1 and IRF3, leading to a diminished IFN response and supporting the
idea that conformation of the ligand-STING complex has a role in activating the innate immune
response.29

1.7 Putative STING Agonists

1.7.1 Cyclic DiNucleotides (CDNs)
Thus far, a significant proportion of scientific study of CDNs has mainly focused on the
positioning of the nucleotide linkages between GMP and AMP, with particular emphasis placed
on 2’,3’-cGAMP, the endogenously produced native ligand of STING (Figure 5).1
From these studies, two hypotheses emerged (1) 2’,3’-cGAMP exhibits a high affinity for
the STING protein due to the many interactions between them, particularly a free 3’-OH group
from GMP that interacts with serine-162 deep in the cleft generated by the dimerization of
STING which may aid in explaining why a 2’,5’-phosphodiester linkage is advantageous within
the STING LBD, as it is hypothesized to help anchor and position 2’,3’-cGAMP to the bottom of
the pocket when initially binding to increase the chances STING closure will occur, and (2)
based on binding affinity data, mutations that occur within the binding pocket, exemplified by the
R232H allele, can alter STING’s affinity with CDNs, especially CDNs composed of differing
phosphodiester linkages (e.g., 2’-5’- compared to 3’-5’-phosphodiester connections).1
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Figure 5. 2-D chemical structures of c-di-GMP, 2’,3’-cGAMP, and 2’,2’-cGAMP.
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1.7.2 Limitations of CDNs as a Therapeutic
With that said, for CDNs to be a practical therapeutic, researchers will be compelled to
address the limitations of endogenous CDNs, for example, their substandard cellular membrane
permeability (given STING is a cytosolic CDN sensor) and their fast clearance from the human
body.1 As a result, synthetic cyclic dinucleotides were formulated by academic laboratories1 and
commercial institutions1 to address these challenges by introducing structural diversity to cyclic
dinucleotides.1 Previously investigated CDN alterations have included the modification of the
phosphodiester linkages (e.g., with phosphorothioates, boranophosphates, carbamides, and
thiocarbamides), changes to the free hydroxyl position on the ribose ring with substituents, as
well as adding uncanonical-, modified-, and non-purine bases.1

1.7.3 Murine STING Specific Agonist
As mentioned in a previous section, STING activates the innate immune response by
potentially priming antitumor T cells through activating the cGAS-STING pathway.40 Loss of
expression or function of STING could alter, impair, or terminate STING’s antitumor capabilities
and allow tumor growth to escape immunosurveillance.40 Thus, new insights into the role STING
plays as a potential modulator of antitumor immunity have provided an incentive in examining
and analyzing whether medicinal compounds that agonize a STING response could have utility
in treating cancer(s).40

1.7.4 DMXAA
5,6-dimethylxanthenone-4-acetic acid (DMXAA) was discovered from the precursor
compound xanthenone-4-acetic acid (XAA) when a dimethyl substitution at the fifth and sixth
positions of the xanthone scaffold generated DMXAA.1 These substitutions were inspired by the
compound flavone-8-acetic acid (FAA), which exhibited non-steroidal anti-inflammatory and
antitumor properties but failed in its human clinical trial.1
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When synthesized, DMXAA was shown to possess potent disruption to tumor
vasculogenesis41. T cells played a role in mediating a DMXAA response in mice.42 DMXAA
interacted in a 2:1 stoichiometric ratio with murine STING (mSTING) (i.e., two DMXAA
compounds bind to one mSTING protein).42 Once identified, DMXAA then progressed through
human clinical trials but was surprisingly prematurely ended in phase III.1, 43 The reason was
DMXAA could only bind to mSTING and not hSTING, notwithstanding the 68% amino acid
sequence identity and 81% structural similarity between mSTING and hSTING,44-45 lead
researchers to hypothesize that subtle differences between mSTING and hSTING needed to be
ascertained to explain why DMXAA activated mSTING but failed to bind to hSTING.
Hence, subsequent molecular dynamics (MD) simulations were conducted to understand
the structural differences between mSTING and hSTING, leading to DMXAA’s insensitivity.
Researchers conducted two separate sets of simulations to answer two specific research
questions (1) why a single mutation within the lid region, a G230I substitution, restored
DMXAA’s sensitivity to hSTING and (2) how discerning the propensity of STING to be in an
active or inactive state could address the failure of DMXAA as an hSTING agonist.46
In the first set of simulations, researchers investigated the G230I substitution of hSTING
based on the amino acid difference between mSTING and hSTING at the 230 residue position.
The substitution replaces a glycine in hSTING with isoleucine present in mSTING.46 Once the
simulations were analyzed, researchers surmised a decrease in entropy at the 230 amino acid
position in mSTING where the glycine to isoleucine variation occurs, providing enough of a
steric barrier within mSTING’s lid region to prevent one of the two stoichiometric equivalents of
DMXAA from exiting the mSTING LBD46 and corroborated further by a separate MD simulation
of a G230I substitution in hSTING that restored DMXAA’s sensitivity to the hSTING protein.46
However, researchers noted that without the hSTING G230I substitution, one of DMXAA’s two
stoichiometric equivalents would eventually be displaced from the hSTING LBD and thus
unravel the holo STING dimer conformation.46
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Moreover, additional simulations suggested to investigators that mSTING in its apo form
(unbound to a ligand) prefers to exist in a more closed-active conformation rather than and
opposed to hSTING in its holo form (bound to a ligand), which researchers suggest prefers to
occupy an inactive conformation even when complexed with cGAMP.46 These two findings
underscore the challenges researchers face when screening and optimizing potential hSTING
agonists but are especially acute when developing compounds screened and identified with
mSTING experimental or computational models.

1.8 Current Challenges and Future Prospects

1.8.1 Developing STING Agonists
As a reminder, CDG prefers to activate STING in an “open” conformation where the two
STING monomers or “arms” comprising the STING dimer are brought closer together when
CDG is bound, compared to the “closed” conformation induced by 2’,3’-cGAMP, and may serve
as a suboptimal conformation for STING activation.9 Moreover, since the emergence of
amidobenzimidazole (ABZI) as a potential STING agonist, scientists have reconsidered if the
closure of the lid region of the STING dimer is “critical” to STING activation, given that both
CDG and ABZI can bind and activate the immune signaling cascade when STING is in its open
conformation.1, 47 The potential realization that lid organization and closure are not essential to
STING’s role in producing an IFN response presumes that STING modulators can possess a
broad range of binding affinities across STING species and alleles, increasing the difficulty of
discovering modifications that improve ligand binding to STING’s LBD.
As of yet, a tangible mechanism for STING activation is not well-known; a few side chain
residues within the dimerization region serine-162 and tyrosine-167, as well as threonine-263
that resides in the deep cleft formed by the STING dimer, have been suggested as critical
interactions observed in both the open and closed conformations of STING.1 In fact, STING’s
ability to exist in many conformations that induce an IFN response gives justification to consider
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that both ligand binding and activation of STING may be intrinsically dynamic to how STING
interacts with potential ligands. Thus, the previous characterization that the “open” conformation
of STING is inactive isn’t necessarily applicable when a ligand preferentially binds and stabilizes
a more open conformation of STING relative to the closed conformation induced when STING
binds to 2’,3’-cGAMP, an idea that should be considered when screening for and designing
potential STING agonists.
Finally, what can further complicate the development of STING agonists is the potential
propensity for hSTING to exist in its open conformation, a conformation ligands preferentially
bind to induce dimerization of the STING protein, and as we shall soon see, a conformation not
exactly hospitable for drug intervention by small molecules.

1.8.2 Developing STING Antagonists
When developing STING antagonists, the physical characteristics of STING create
additional complications with a total solvent accessible surface area (SASA) of the apo STING
protein computed to be 390 square angströms that potentially requires a ligand of 700 Da in
size to occupy.48 Moreover, the total volume of the STING LBD is calculated to be 952 cubic
angströms and bolsters the notion that a large complex ligand is needed to occupy the STING
LBD.48
Furthermore, equally important to consider is the fact that 60% of the SASA of STING is
composed of polar amino acid residues, especially in the deep cleft linking the two STING
monomers, which may limit an antagonist's ability to generate hydrophobic interactions in the
dimerization and lid regions that propel the binding affinity of potential antagonists (consider
tyrosine-167 and tyrosine-240 in the dimerization and lid regions respectively of each STING
monomer as examples).48
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1.8.3 Screening and Optimizing STING Modulators
With this in mind, a sensible and practical strategy in designing STING modulators is to
leverage the symmetrical structure of hSTING by computationally screening potential smallmolecule using a 2:1 binding stoichiometry site-restricted modeling protocol that allows
researchers to dock small compounds to various conformations of hSTING. Subsequent
chapters will discuss the site-restricted docking protocol used for screening and potentially
optimizing putative STING modulators.
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Chapter 2
Development of Computational Models

2.1 Best Practices for Computer-Aided Structure-Based Drug Discovery
Molecular modeling is a discipline that investigates a molecular system’s behavior. When
applied to drug discovery, molecular modeling aims to accurately, precisely, and reproducibly
represent the behavior of biological molecules. The insanity of the enterprise is apparent when
you consider that biological molecules exist within a multitude of interconnected networks that
culminate in making living organisms possible.
Therefore when starting any virtual structure-based drug discovery campaign, selecting
and preparing computational models are essential factors in cutting through the complexity of
biological systems. However, computational methods depend on experimental data to develop
initial structures suitable for potential drug discovery campaigns. Although created in less than
ideal situations, those initial structures require preparation before a modeling campaign can
commence. This thesis focuses on the innate immune adaptor protein STimulator of INterferon
Genes for possible modulation.
Consequently, target selection and proper identification of a potential therapeutic target
is critical and necessitates an exhaustive literature review of the specified biological system
under consideration (e.g., a protein) and any relevant ligands that bind and modulate that
system. An encouraging starting point for any virtual screening protocol, in general, is identifying
and preparing high-resolution protein structures for computational use, ideas that will be
introduced and expanded upon throughout this chapter.
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2.1.1 Selecting a Suitable Target
When selecting a suitable target, crystal structures with bound ligands (termed holo
structures) generally outperform ligand-free crystal structures (termed apo structures) as the
geometries of critical structural elements for potential binding are better defined when present in
the bound state than in the unbound state.49-50
However, suppose no holo structures exist for the target of interest. In that case, tools
that search for possible ligand-binding domains can be employed using a binding site detection
algorithm. SiteMap51-52, a binding site detection algorithm within the commercially-licensed
Schrödinger software suite, was used extensively in this computational study as it’s designed to
search the three-dimensional structure of a protein for potential binding sites and, after
assessing the protein, highlights regions that may be appropriate for interacting with
hydrophobic and metal-binding functional groups, as well as hydrogen bond donor/acceptor
regions that aid in determining the placement of docking grids to evaluate chemically distinct
scaffolds.51-52
Finally, it is best to choose starting structures with small binding domains bound with an
enclosed ligand that complements the binding pocket53-56. Ideally, the native ligand, as these
structures tend to perform better with molecular modeling protocols than flat, large, and solventexposed ligand-binding domains where protein-protein57-58 and protein-peptide59 interactions are
found, as targeting these surfaces can often be complex and lead to frustratingly unproductive
outcomes.60

2.1.2 Preparing Protein Structures and Ligands for Modeling
Once a protein structure is chosen, modeling with the initial protein system is not
customary as errors and uncertainties can propagate throughout a modeling study if not
adequately refined. Therefore, the preparation of proteins and ligands (for self- or crossdocking) is required for any computational protocol. Software from open-source or
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commercially-licensed methods can be used as each has a defined methodology to index the
structural information of a protein system (e.g., atoms, molecules, residues, chains, etc.).
The commercially-licensed Schrödinger software suite uses scripts for protein
preparation, termed the “Protein Preparation Wizard,” that can be used to streamline the
modeling workflow and aid in addressing common concerns found in high-resolution protein
structures, e.g., adding hydrogens, formal charges, bond orders, managing the poor placement
of atoms, sampling degrees of freedom of side-chain residues that are ambiguous in the protein
structure, assigning tautomer/ionization states, the treatment of amino acid residues with
missing electron density or are missing altogether, ways to treat crystallographic water,
hydrogen bond optimization, and the overall energy minimization (i.e., relaxation) of the protein
structure can be considered.61
Accordingly, protein preparation protocols should account for crystallographic artifacts,
structural errors, and uncertainties that may intentionally and unnaturally influence the system’s
crystallographic packing by inducing folding events that are not seen in nature and possibly
affect protein function.
Therefore great care should be observed when refining a protein system as conditions to
generate these constructs result from consequential experimental conditions unavoidable in the
crystallization process that do not conceivably and accurately represent a biological
environment. In general, buffer components, e.g., salts, from the crystallization process should
be removed from the structure, cofactors should be removed unless involved in ligand
identification, and hydrogen atoms (from the protein backbone or existing on amino acid side
chains) should be modeled to correctly protonate62, 64 the target of interest, as proper protein
protonation is vital to increasing the substantive predictions of van der Waals (vdW) surfaces
and dipole moments of the ligand-binding pocket.63
Moreover, since protein crystal structures are deposited to structural databases, such as
the Protein Data Bank (PDB), the submitted constructs are often represented as a structural
average of an ensemble of protein conformational states, conveniently illustrated as a single
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structure. However, high-energy conformers within these structural databases can exist due to
the positional averaging process from overlapping protein atoms that should be factored into the
preparation process of a target.65
Appropriately, the best practice to solve this potential issue is to cautiously minimize the
energy of the protein to lead the system to a less volatile state by equilibrating the structure via
molecular dynamics (a protocol that simulates the motion of molecules and endeavors to
reproduce the dynamics of a system) before a modeling study is to begin.66 Accordingly,
experimentalists and theorists must collaborate, as experimentalists require computational
modeling to verify aspects of their crystallographic data. At the same time, they are providing
theorists with high-quality structures for molecular modeling.

2.2 Ligand Docking: An Introduction
Ideally, molecular docking (colloquially referred to as “docking”) evaluates the “fit” of a
molecule (e.g., a ligand) in a protein binding site. It frequently entails sampling many possible
configurations of a potential ligand (i.e., the three-dimensional arrangement of atoms in a
molecule). Each configuration is eventually scored to estimate the ligand’s “fitness” (i.e., how
well a ligand complements the shape and chemical properties of the binding domain) using one
of a variety of scoring functions that can examine different aspects that affect ligand binding
(e.g., hydrophobicity, charge, and induced-fit effects).67-69, 70-72, 73, 74-84
Molecular docking serves as a profound tool in the drug discovery and design process,
which can take 10-15 years85 to complete and cost an estimated $2-3 billion dollars86 to
generate a de novo therapeutic for human use, and that’s before one considers the high rate of
attrition and adaptive regulatory landscape a potential drug must satisfy to become
commercially available.86
The advantage of molecular docking over experimental techniques allows interested
parties to virtually screen billions of compounds to the target of interest under investigation.
Once a hit is identified (a ligand that potentially binds to the target), the compound can be
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experimentally verified and optimized to maximize the ligand's pharmacokinetic and
pharmacodynamic properties that seek to lower the drug’s attrition rate in later stages (i.e., preclinical and clinical phases) of the research and development (R&D) process.
These concerns have led to a fervent discussion on how public-private partnerships87,
drug-repurposing85-86, drug optimization88, and risk mitigation89 during the drug discovery
process can alleviate the global disease burden. Not without its issues, docking protocols
commonly under-sample ligand configurations, ignore neglected energetic terms (e.g., ligand
strain), and use approximate methods (fixed potentials or fixed grids comprising geometries and
properties of a target) to decrease the computational time to screen large-scale compound
libraries (potentially containing billions of compounds).90-91
Additionally, these approximations lead to known errors in how docking methods assess
ligand-protein complementarity, specifically the relative binding free energy calculated for each
ligand during the docking protocol, and generally cannot be relied upon to rank compounds from
large- to small-scale compound libraries.92-93 Furthermore, docking protocols must balance the
speed/cost of the scoring function and the desired accuracy of the algorithm, making it a
challenging endeavor when no prior notions of cross-docking a ligand to a target exist to assist
with the search.
Despite these facts, what docking can do and what their designed purpose is for is to
differentiate between ligands that have a reasonable chance to interact with the target from the
more considerable volume of compounds that are unlikely to stabilize a ligand-protein complex
(i.e., “finding a needle in the haystack”). Since the true success of any virtual screening
campaign is in identifying hits using a prepared computational model and then experimentally
verifying the docked compound binds to and modulates (activates or inhibits to some degree)
the activity of the target of interest. As a result, control calculations are required for the success
of any computational study, as experimental controls are for empirical methods. Nevertheless,
this step does not ensure the future success of the campaign. Instead, it allows investigators to
surveil apparent sources of error to understand where their strategy went awry.
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Computational controls are met when an optimized binding domain can rank known
actives that reasonably predict and generally measures up to the crystallographic pose of the
known active, ideally the co-crystalized ligand from the prepared protein model serving as the
positive or negative control, against inactive decoy molecules that may be property-matched
(share similar physical properties as the active compound but are unrelated topologically) and
speculated to be non-binders.94
When assessing the validity and pose fidelity of a ligand serving as a control, the
predicted binding pose provided by the chosen docking procedure can be examined
qualitatively by visually inspecting interactions known to be critical for binding between the
ligand and the protein, or in the best-case scenario, can be quantitatively calculated by root
mean square deviations (RMSD) between the experimentally determined pose from a known
crystal structure and the predicted pose provided by the specified docking technique.95
As a reminder, the overall success of a docking study is gauged by the investigator's
methodologies to uncover novel chemical scaffolds that can be shown to experimentally bind to
the target of interest using binding and cellular assays.63 A common artifact to control when
experimentally screening compounds is colloidal aggregation96, 97, where ligands aggregate and
sequester proteins with little selectivity, resulting in either inhibition98-101 or activation102-103 of the
protein targeted in the experimental study, a task at which computational techniques are not
equipped to manage and where experimental controls are still required in drug discovery
campaigns.

2.3 Refinement of Human STING Models for Molecular Modeling
Previous computational studies have been undertaken to prepare, equilibrate, dock, and
experimentally verify computational models of human STING (hSTING) to screen for potential
modulators (agonists or antagonists). To reiterate the aim of the study, STING represents a
crucial therapeutic target for human disease, given STING’s role in signaling the activation of
the innate human response.
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Discovering novel chemotypes that positively modulate STING may serve as potential
anti-cancer agents. In contrast, chemical scaffolds negatively affecting STING's activity may act
as potential agents against auto-inflammatory and auto-immune disorders. Thus screening
potential small molecules with previously developed computational models and a site-restricted
docking method are mentioned in Section 1.8.3 and further described in later sections of this
chapter.

2.3.1 Protein Preparation of STING Models
Human STING (hSTING) protein models were prepared with the commercially-licensed
Schrödinger software suite by downloading available protein structure coordinates from the
Protein Data Bank (PDB).104-105 The hSTING computational models were generated from the
PDB codes provided in Table 2.
Potential agonist models of hSTING are represented by closed confirmations: 4KSY
(R232 allele, co-crystallized with 2’,3’-cGAMP),36 4F5D (R71H-G230A-R293Q allele, cocrystalized with c-di-GMP),32 and 4LOH (R232H allele, co-crystalized with 2’,3’-cGAMP).37 The
potential antagonist's model of hSTING is presented by open conformation 4EMU (R232H allele
in its apo form).31
A specific molecular dynamic (MD) simulation was executed to simulate 2’,3’-cGAMP
structural effects on the R71H-G230A-R293Q (HAQ) allele by incorporating the 2’3’-cGAMP
bound 4KSY hSTINGWT structure into the variant hSTINGHAQ isoform. The 4EMU hSTINGREF
apo form of STING was used to cross-reference conformational states provided by the MD
simulations for all protein systems. All PDB systems listed in Table 2 were prepared using the
Protein Preparation Wizard (PrepWizard)61, 64, 106 mentioned in Section 2.1.2 and visualized
using Schrödinger’s graphical user interface (GUI) Maestro107.
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Table 2. Human STING (hSTING) Structures Used for Molecular Modeling
PDB Code

4KSY

4F5D

4LOH

4EMU

Structure Type

X-ray Difffraction

X-ray Difffraction

X-ray Difffraction

X-ray Difffraction

Crystalized Ligand

2',3'-cGAMP

c-di-GMP

2',3'-cGAMP

Apoprotein (Apo)

Resolution

1.88 Å

3.00 Å

2.25 Å

1.90 Å

Conformation

Closed

Closed

Closed

Open

Residue Length

152-336

153-340

155-341

149-341

230

G

A

G

G

232

R

R

H

H

Residue Variations

R232

G230A

R232H

R232H

Publication Date

June 12, 2013

Jun 27, 2012

August 14, 2013

June 13, 2012

Reference

36

32

37

31

LBD Variations

31

Cofactors (e.g., phosphate and sulfate ions), additional protein structures (STING
monomers, dimers, etc.), and ligands were removed if present within the crystal structure.
Substandard contacts were lessened by deleting the original hydrogens from the protein
structure and assigning bond orders (including disulfide bridges) before protonation108-110.
Protein-bound water molecules within the PDB system were retained as they engaged in
direct hydrogen bonding with polar and charged amino acids of the protein’s binding surface for
researchers to determine appropriate protonation states of amino acid side chains for initial
hydrogen bond optimization and Schrödinger’s Prime111-113 software package was used to add
and optimize any missing amino acid side chains in the chosen STING protein systems. Once
side-chain optimization was complete, hydrogen atoms were added to the protein, any
remaining cofactors, and any structural (i.e., protein-bound) waters. The PROPKA64 software
program was used to predict ionization states of proteins at physiological pH (7.4), and
ProtAssign was used to optimize hydrogen bonding.
Once the automated assignment and optimization of hydrogen atoms had concluded,
each protein system was visually inspected to flip amino acid residues and change protonation
states at protein-protein interfaces within the system if/when appropriate.

2.4 Protein System Equilibration via Molecular Dynamics
As a reminder, structural databases such as the Protein Data Bank (PDB) contain crystal
structures that are single averaged snapshots of a dynamic protein system. The deposited
protein represents the statistical average of a combination of conformational states generated
during the crystallographic process. As a result, high-energy atoms can exist within these
structures from particles overlapping when the representative protein is generated65,
occurrences energetically unstable for modeling the initial system.
Accordingly, best practice suggests equilibrating or " relaxing” the protein structure via
molecular dynamics (MD) before modeling.66 MD simulations were performed for all hSTING
protein structures in Table 2 using two Nvidia GeForce GTX 1080 Ti video cards executing the
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GPU accelerated Desmond Molecular Dynamics Systems software available in the Schrödinger
software suite.66, 114-116 In preparation for the simulation, a cubic simulation box is generated that
extends at least 10Å from the protein, where periodic boundary conditions are applied to TIP3P
waters117, and an OPLS3 all-atom force field is then imposed on all atoms in the system.118
hSTING MD simulations are run at 310 K and the constant pressure of 1 atm. They are
energetically minimized, followed by numerous restrained minimizations to randomize each
system before the final equilibration and simulation steps. All hSTING models were simulated
for 250 nanoseconds (ns). Equilibration of each hSTING protein system was visually observed
by the asymptotic behavior of its root mean square deviation (RMSD), potential energy profile,
the radius of gyration (Rg), and trajectories as compared to the protein’s root mean square
fluctuations (RMSF) throughout the simulation.130

2.5 Computational Techniques and Strategy
When the equilibrated hSTING computational model is established, a clustering method
to determine the hierarchical average linkage between MD simulated conformation states was
performed to create a single representative structure for each human STING (hSTING) system
listed in Table 2.
Additionally, to review the consistency of side-chain protonation within the equilibrated
model, the program PROPKA was implemented at physiological pH (7.4). Once consistent sidechain protonation states of each equilibrated model are observed, the models can then be used
for consensus docking to five distinct and complementary methods, standard precision (SP) and
extra precision (XP) rigid receptor docking, induced-fit docking (IFD), quantum polarized ligand
docking (QPLD), and the molecular mechanics/generalized Born surface area (MM-GBSA)
protocol.
Thinking that only one molecular docking method is sufficient to depict the potential
probability that a ligand will bind/interact (e.g., adhere) to the target is a common misconception.

33

However, as Section 2.2 describes, there is an inherent error in calculating binding energies
when virtually screening compounds as potential modulators of a target.
Moreover, one scoring function does not usually contain all the necessary energetic
terms to fully and accurately outline a ligand’s attributes and affinities to a target. The principal
aim of molecular docking is to discover, design, and distinguish ligands as plausible
therapeutics by quantifying the amount and relative strength of any prospective interactions a
ligand induces with the target of interest. Rigid receptor docking (RDD) will be the first molecular
docking protocol discussed as it is simple and frequently implemented. RDD instructs the
receptor (e.g., a protein) to be held in a fixed spatial position. At the same time, the ligand’s
conformational states are marginally sampled, selected, and energy minimized to produce an
optimal pose for the ligand in the selected binding site.

2.5.1 Rigid Receptor Docking
When docking with a rigid receptor protocol, the model system must be in its lowest
energy conformation, i.e., in its most expected form, as the protocol is sensitive to the system's
initial state. Furthermore, conformational sampling of a ligand, target and the potential inducedfit effects between the ligand and the target should be examined to interpret the dynamics of the
ligand-protein complex.
As a reminder, computational techniques try to balance the computational method's
accuracy and speed. As a result, molecular docking grids can be used to address each
consideration. A docking grid is a three-dimensional (3D) lattice that contains a binding site's
critical interactions. A docking program can then use the generated docking grid to approximate
and scale factors relevant to calculating a ligand’s relative binding free energy from the specified
docking formula that scores and ranks compounds by quantitatively estimating and summing
the totality of a ligand’s interactions with a target into a single numerical value.
The GLIDE67-69, 119 (Grid-based LIgand Docking with Energetics) software program,
developed in 2004 by Friesner et al., included as the flagship docking protocol in the
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commercially licensed Schrödinger software suite is a well-regarded grid-based docking method
due to its comparable rate of pose fidelity and energetic accuracies when screened against a
target’s native ligand.120
A key to GLIDE’s methodology is generating a collection of grids representing the
geometries and properties of a target’s binding site. Then distinctive to GLIDE, executes a
systematic search of a docked ligand's positional, orientational, and conformational space.
The conformation that best satisfies the attributes of the generated grid is then further refined by
a Monte Carlo (MC) sampling method, which obtains a numerical value for analysis by
implementing an approach that “randomly” samples a system to resolve queries that are
plausibly deterministic in scope (e.g., the energetics of a ligand).
For that reason, the MC method is best suited for sampling the conformations of ligands
as the “random” moves generated when executed can deftly cross considerable energetic
barriers (e.g., in torsional rotations), and if the move fulfills the criteria, the system (i.e., the
ligand) accepts a change in condition. However, the aptitude of the procedure can also be its
greatest weakness and prone to error (e.g., when stuck in local energy conformations)121, as the
method depends on the system's complexity. The behavior being examined, e.g., the energetic
window associated with protein folding vs. ligand conformations, also makes this method illsuited to probing the conformational states of proteins.
Fortuitously, MC’s ability to illuminate local degenerate energetic states may be helpful to
and particularly adept in examining the energetics of molecules in biochemically relevant
environmental conditions122 (i.e., bulk water systems at 310K, e.g., humans) and why it's utilized
to refine ligand conformations within the GLIDE docking protocol.
Once sampled, the ligand’s torsional space is explored to generate ample ligand binding
poses. Alternative ligand conformations are analyzed using hierarchical filters and a rough
Emodel calculation.67-69 After the rough scoring stage, the ligand proceeds through additional
minimizations steps to estimate the final relative binding free energy of the ligand with GLIDE’s
proprietary energy function, GLIDEScore.67-69
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As a result, GLIDE was used in this study due to its extensive literature review of its
proprietary algorithms, synergetic workflow across the entire Schrödinger software suite, and,
most importantly, the researcher’s opportunity to access an active software license.

2.5.1.1 Standard Precision and Extra Precision Docking. Standard Precision (SP)
docking is GLIDE’s original scoring function using hierarchical filters to score, minimize, and
assess the final energetics of various ligand poses (i.e., a ligand’s position and orientation in
space). The SP docking algorithm quickly estimates a ligand's binding affinity by systematically
searching and evaluating the shape and chemical property complementary of the docked ligand
and the target120 and remains a reliable protocol according to benchmarking studies.120
Moreover, the reasonably fast pace of the process (an estimated 10-15 seconds per
ligand) seeks to balance the speed requested (i.e., computational cost) and the accuracy
required when executing the protocol. However, SP docking can experience a significant
slowdown in tempo as ligand size and complexity (e.g., rotatable bonds) increase.67-68 The
objective of SP docking is to reduce false negatives in a virtual screening campaign by
implementing a “softer” scoring function to accommodate ligands of unknown quality that may
have a reasonable chance of binding to the target but are not yet structurally or chemically
optimized.
As a result, the SP algorithm is the ideal first method for any virtual screening campaign
due to its reliability, speed, and applicability in screening large compound libraries for potential
hits (e.g., binders of the target of interest). However, the SP docking method was later refined
by modifying the GLIDE scoring function that sought to resolve more complex hydrophobic
contacts present in hydrophobic enclosures, e.g., within an enclosed portion of a protein binding
site. Schrödinger eventually termed the refined method as Extra-Precision (XP) docking.69
The advancement of XP docking provided a computational approach to reduce the
number of false positives in virtual screening campaigns by evaluating potential ligands on how
well each compound can complement a specific conformation of a receptor (e.g., the difference
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between an active and inactive protein conformation). The XP scoring function executes the
objective by incorporating scoring terms that model the effects of a hydrophobic enclosure,
protein-ligand structural motifs via complex (e.g., neutral and charged) hydrogen bonding
interactions, and water desolvation to improve virtually screening algorithms to interpret binding
sites with substantial hydrophobic character and complex hydrogen-bonding networks.69
However, the improved virtual screening tool increases its computational cost by
sacrificing speed (an estimated 2 minutes per ligand) with the same dependency of ligand size
and complexity (e.g., rotatable bonds) as discussed for SP docking.69 Consequently, XP docking
is ideally situated to focus virtually screening campaigns on ligands well-suited to binding to a
specific protein conformation where complex hydrophobic interactions may exist.
Notwithstanding, the fundamental drawback of using a rigid receptor docking program is
its inability to account for protein flexibility. Each algorithm assumes the protein is a static entity.
However, in reality, the protein exists as a dynamic structure. In addition, while GLIDE attempts
to sample potential ligands exhaustively, accuracy issues remain in pose prediction and
significantly increase when ligand size and complexity increase. Moreover, arbitrary scoring
functions used in virtual screening campaigns are still limited by unfavorable errors (an average
of ± 2 kcal/mol disclosed by Schrödinger) in calculating relative binding free energies when
normalized to experimentally determined binding free energies. Theoretically derived scoring
functions' are subjective and discretionary and should encourage healthy skepticism toward any
docking result.
A point further supporting why proper preparation of a computational model (e.g.,
protein), the ligands to be virtually screened, as well as the appropriate selection of a control
compound(s) (e.g., the native ligand) for renormalization is critical to potential error indexing.

2.5.2 Induced-Fit Docking
Speaking of protein flexibility, induced-fit docking (IFD) is a software protocol developed
by Schrödinger that combines GLIDE’s ability to account for ligand flexibility in molecular
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modeling due to the systematic conformational search procedure of the ligand with the
refinement module of Prime to resolve a target’s flexibility when adapting to the shape and
binding mode of a ligand, by deleting residues that surround the docked ligand, the program
reconstructs the binding domain by integrating energy minimized residues within a specified
cutoff distance from the docked ligand.70-72, 123
The two goals for induced-fit docking are to (1) generate accurate ligand-protein binding
modes of known active compounds that cannot be adequately assessed with a rigid structure of
a target of interest if the target exists in multiple biologically active/inactive states (e.g., when
generating potential STING agonists to the closed conformation of the STING dimeric protein)
and (2) recover false negatives (i.e., true binders that are poorly scored with other scoring
functions) otherwise excluded in a virtual screening protocol when assessing different
conformations of the target of interest via rigid receptor protocols.72
The IFD protocol developed by Schrödinger attempts to model the induced-fit effects
when a ligand binds by altering the target of interest’s side-chain residues to improve the
interactions between the ligand and the target.72 As a result, the IFD protocol seeks to enhance
the capability of its GLIDE scoring function when calculating the relative binding free energies
when protein flexibility is a crucial component to binding the target, in addition to predicting
possible binding modes that are biologically relevant.72
IFD has four procedural steps, all of which have limitations/challenges (1) initially
sampling the ligand with a reduced van der Waals potential and temporarily replacing highly
flexible amino acid side-chains with alanine, (2) sampling the target of interest with each ligand
pose generated in step one, (3) redocking potential ligand poses to low-energy IFD structures
produced in step two, and (4) scoring potential ligand poses by considering their docked energy
as determined by GLIDE with their energetic strain and solvation terms assessed by Prime.113
While the IFD protocol may improve potential ligand-protein binding modes, it has a
significant disadvantage when considering the amount of time required to complete the
simulation, which can be measured in hours for a single compound run on a single processor.72
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Therefore, it's in the researcher's best interest not to use the IFD protocol as a general method
for molecular modeling but as a specialized strategy to model only flexible targets of interest
and rely on rigid receptor docking methods for inflexible ones.

2.5.3 Quantum Polarized Ligand Docking
Virtually screening compound databases containing millions, if not billions of
compounds, is often tricky,73 especially when physical chemistry-based methods approximate
interactions between a ligand and its target of interest.67-69, 73, 124-129 One such example is the
approximation of ligand polarizability when atomic charges are calculated with a molecular
mechanics-based force field, such as the Schrödinger-based Optimized Potentials for Liquid
Simulations (OPLS) series of force fields, which tries to strike a balance between the speed and
accuracy of the algorithm.73
However, in optimization protocols, it is essential to use the additional computational
time to calculate ligand charges when polarization factors into ligand binding, as docking
methods such as GLIDE rely on molecular mechanics (MM) to speed up the calculation at the
expense of reduced accuracy in calculating a docked ligand’s relative binding free energy.73
As a response, Schrödinger developed the Quantum Polarized Ligand Docking (QPLD) protocol
using a hybrid quantum mechanics/molecular mechanics (QM/MM) approach. Defining the
ligand within the QM region provides the potential for increased accuracy in calculating ligand
charges while leaving the protein expressed in the MM region so as not to substantially increase
the computational run time of the screening campaign.73
The QPLD procedure first generates several ligand conformations through conventional
MM-based docking methods, e.g., GLIDE. It then executes a single-point energy calculation
(i.e., the potential energy of a molecule) for each ligand-protein complex in a specified
conformation (e.g., atom arrangement).73 New partial atomic charges are then derived from
electrostatic potential fitting between the charges calculated for the ligand in the QM region and
the protein system in the MM region.73
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The new QM-calculated charges are then incorporated for each ligand conformation.
Each ligand is then re-docked, using the QM-calculated charges, and scored to improve pose
generation and relative free energy calculation in instances where protein-induced ligand
polarization occurs.73 Moreover, when compared to IFD, QPLD prioritizes accuracy over the
computational speed of the algorithm with simulation times for a single compound measured in
hours per molecule.
In addition, QPLD is a rigid docking protocol and provides no considerations regarding
how the flexibility of the target may factor into the process and should be followed up with IFD
docking when the target is known to be flexible when ligands bind.73

2.5.4 Molecular Mechanics and Generalized Born Surface Area
The final docking algorithm this thesis will consider is molecular mechanics combined
with Generalized Born Surface Area (MM/GBSA), an implicit continuum solvation medium where
the average properties of a solvent (e.g., water) are modeled using less computationally
expensive methods when compared to explicit methods of solvation that employ hundreds or
thousands of water molecules to simulate liquid environments (e.g., a human cell’s cytosol).75
Explicit solvation methods increase the complexity of a computational model and thus
the run time for a single free energy simulation, a critical disadvantageous to its applicability in
high-throughput virtual screening campaigns.75 However, the development of the MM/GBSA
protocol allowed free energy simulations to be run faster by approximating a system's
thermodynamic properties when the solvent's atomistic detail is not central to account for
solvation effects.75
When analyzing multiple ligand-target conformations, either through molecular dynamic
(MD) or Monte Carlo (MC) methods, executing separate minimization procedures on (1) the
receptor, (2) the ligand, and (3) the ligand-protein complex using MM/GBSA implicit solvent
models allows the method to estimate the change in the system's relative binding free energy
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when a target is in its bound-state, reducing the simulation time when compared to simulations
that use a solvent explicitly.74
Notwithstanding, MM/GBSA is mired in numerous assumptions and approximations
embedded within its protocol, making it difficult for the method to gain broad applicability for
various computational systems as the performance varies when applied, and difficulties arise
when trying to correlate computationally derived and experimentally determined free energy
values. In addition, attempts to improve accuracy with a broader variety of computational
models have led to various initiatives to refine MM/GBSA, including improved models of
solvation81, QM calculations79, and polarizable force fields.77 However, these attempts have led
to nothing more than discouraging results.
Therefore, the computational best practice before using MM/GBSA is to know the
investigated protein’s solvent and electrostatic conditions, as well as to analyze multiple
receptor conformations of the protein generated from molecular dynamic or Monte Carlo
simulations to capture dynamic system changes to validate the applicability for implementing
this computational technique.74

2.6 Designing Agonist/Antagonist STING Models
Previous computational studies have utilized MD simulations on multiple STING
conformations to gain a more thorough insight into how STING interacts with potential
ligands130, as well as possible protein-protein interactions from STING's binding partners
discussed in Section 1.2.131
When reviewing the MD trajectories of CDN-STING complexes of apo and holo
hSTING130 in Table 2, commonalities had arisen between STING isoforms and control ligands
(e.g., 2’,3’-cGAMP, 2’,2’-cGAMP, and CDG) previously examined. This led to the idea that
distinct protein conformation-induced binding mechanisms may occur when ligands bind to
hSTING. A proposed mechanism for initial CDN binding is within the deep cleft of the pocket,
where polar residues serine-162 and threonine-267 are located. However, the structural
41

differences within CDNs, e.g., the phosphodiester linkages between the two nucleotides, may
assist in explaining the vast difference in binding affinity of CDNs to STING, e.g., 2’,3’-cGAMP’s
low nanomolar (nM) vs. 2’,2’-cGAMP and CDG’s low micromolar (µM) affinity.1
A clear metric was then conceived to gauge the potential activation of STING by
measuring the distance between the alpha carbons of a histidine-185 residue located in each α2
helix found on both STING monomers, as the idea assumes the two monomers are brought
closer together when an in-bound ligand interacts with the LBD and instigates hSTING’s lid
region (aa. 219-2491 of each STING monomer) to form a less flexible β-sheet that envelops the
bound ligand giving rise to interactions that result in the cross-promotion of the swapped STING
monomeric domains, eventually closing and decreasing the flexibility of the entire hSTING
structure.30, 32, 36
Upon hSTING’s lid closure, the ligand then endeavors to stabilize the resulting dimer by
cross-promoting interactions with arginine-232 to tighten and encourage further inflexibility of
the resulting holo-STING conformer relative to its apo form. Consequently, the proposed binding
mechanism provides the opportunity to create two distinct STING conformations to virtually
screen small molecules (1) for putative agonists that have a preferable affinity for the holo
conformation of STING and (2) for putative partial agonists/antagonists that have a more
suitable affinity to interact with the apo conformation of STING.

2.7 The Site-Restricted Docking Method
Currently, molecular docking programs are limited to docking and scoring single
compounds and are not equipped to investigate ligand dimerization. For that reason, a
straightforward strategy was developed to identify potential dimer complexes to STING that can
be incorporated with established molecular docking approaches, e.g., the Schrödinger software
suite.
First, during a standard virtual screening protocol where the molecule is screened to the
entire ligand-binding domain of the target, an additional screening procedure can be executed to
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restrict the ligand to a monomeric half (termed half-site) of STING’s ligand-binding environment.
Second, as an alternative to virtually screening ligands to a STING monomer, distinct from the
biologically relevant STING dimer, the restricted-docking approach provides a consistent
implementation of the binding site’s electrostatics when ligands are docked against the target’s
full and half-sites.
Third, once the ligand is docked to both the full and half-sites of the STING LBD, an
RMSD calculation between the two generated ligand poses can commence. The purpose of an
RMSD calculation between the full and half-sites would be to quantify the structural differences
between the poses and, combined with their visual representations, demonstrate whether a
screened ligand has a preference for a specified region of the binding site and thus might allow
for another stoichiometric equivalent to interact with the remaining unoccupied volume. If
possible, updated docking grids could be created to include the full site’s ligand pose, enabling
the binding site’s unoccupied volume to be docked with an identical ligand.
Finally, notwithstanding the second stoichiometric equivalent generating a good docked
pose, a composite dimer could then be produced and screened via established docking
protocols by linking the nearest proximal atoms between the two monomeric ligands with a zeroorder bond, a type of bond GLIDE recognizes by applying a distance constraint on the two
identical monomers. The angle and dihedral terms of the zero-order bond do not interfere with
the applied force field as those components are set to zero in the docking procedure, allowing
the newly linked dimer the opportunity to dock into its respective protein conformation and thus
enabling the scoring function to estimate the relative binding free energy of the zero-order linked
ligand dimer (LD).

2.8 How Mutations Affect the Modeling of STING Isoforms
Multiple STING complexes arise for review when considering the various STING alleles
referenced in Table 2. MD simulations were performed on three hSTING variants, the R232
(WT), R71H-G230A-R293Q (HAQ), and R232H (REF) alleles, to understand how specific
43

substitutions occurring in STING LBD explain discrepancies in experimentally determined
binding affinities of bound ligands, e.g., CDNs.130
Profiles containing the per residue RMSD data generated from these MD simulations
graphically demonstrate a significant increase in disorder for the hSTINGWT and hSTINGREF
alleles compared to the hSTINGHAQ variant due to the lower RMSD calculated for position 230
within hSTINGHAQ vs. the hSTINGWT and hSTINGREF alleles.130 The lower RMSD of hSTINGHAQ
may be accounted for due to a binding site G230A substitution within the area that may prevent
the lid region’s hSTINGHAQ allele from fully enveloping a bound ligand. The typical glycine
residue at position 230, a lid region residue in the hSTINGWT and hSTINGREF alleles, is
substituted for alanine in the hSTINGHAQ variant. In addition, the hSTINGREF allele also has a
substitution within the lid where an arginine residue at position 232 is substituted for histidine,
potentially increasing the flexibility of the STINGREF allele’s lid region to an identical result as
hSTINGHAQ when compared to STINGWT.
Accordingly, separate computational models were developed to consider the possible
structural differences between the STING isoforms, including the specified variations within the
previously discussed STING LBD amino acid sequences. After exploring the Protein Data Bank
(PDB), the hSTINGWT, hSTINGHAQ, and hSTINGREF agonist models were developed. The
hSTINGAQ and hSTINGQ alleles were not generated as they did not possess substitutions within
the STING LBD.130 Moreover, isothermal calorimetry (ITC) derived binding affinity values
determining the dissociation constants (KD) for the three control compounds, 2’,3’-cGAMP, 2’,2’cGAMP, and CDG within the hSTINGHAQ allele have not been published. As a result, the
hSTINGHAQ allele was not included for further consideration when comparing the hSTINGWT and
hSTINGREF computational models.

2.9 Selection of STING Isoforms
Analyzing ligand binding to the hSTINGWT and hSTINGREF alleles used five distinct but
complementary energy scoring algorithms (SP, XP, IFD, QPLD, and MM/GBSA). The calculated
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theoretical energies obtained from these algorithms were then used to assess the optimal ligand
scoring function and determine the main STING isoform for use in subsequent virtual screening
campaigns.130
Previous research in Table 3 compares calculated theoretical binding affinities for CDN
control compounds based on the hSTINGWT and hSTINGREF computational models with
published literature values of experimentally determined CDN binding affinities.130 Since the
hSTINGWT allele is the major isoform within the human population1 and the consistency of the
hSTINGWT computational model’s theoretical KD values with the experimentally determined
dissociation constants (KD) of the CDN controls; demonstrated that the MD equilibrated
hSTINGWT model to be the generalized conformer of hSTING to screen putative agonists.130

2.10 The Consensus Docking Approach
Consensus docking is a computational protocol incorporating multiple physical
properties that can affect ligand binding (e.g., receptor flexibility, polarizability, solvent
interactions, etc.). It applies these varying scoring algorithms within an overall virtual screening
campaign, ideally docked to multiple protein conformations, by partitioning the physical
characteristics of a ligand to separately model how those different conditions affect the final
predicted ligand binding pose.130
Additionally, implementing a consensus docking approach may potentially provide
insight into how a ligand and protein interact with each other and how putative binding
mechanisms arise that would otherwise be an arduous and perplexing endeavor when using
only a single scoring algorithm to evaluate the potential affinity of docked compounds.130
A combined conformational ensemble was hypothesized to explain the docking results
when reviewing previously calculated docking scores for all STING control compounds docked
to the hSTINGWT and hSTINGAPO models as the calculated relative binding free energies of
those five scoring methods for 2’,3’-cGAMP, and 2’,2’-cGAMP had a higher correlation with
experimental dissociation constants (KD) of the holo form of STING.
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Table 3. Computational Model Comparison to CDN-STING Binding Affinities
STING
Isoform

hSTINGWT

hSTINGREF

H185 Crystal Distance

H185 Post-MD Distancef

Model KDf

ITC KD

Cellular EC50

(Angstroms)

(Angstroms)

(nM)

(nM)

(nM)

2’,3’-cGAMP

35.0a

37.8

2.4

3.8a

42 (IFNβ mRNA)a

2’,2’-cGAMP

-

43.1

256

287a

16 (IFNβ mRNA)a

c-di-GMP

53.0e

56.5

6377

1210a

538 (IFNβ mRNA)a

2’,3’-cGAMP

34.7b

39.3

784

5300b

42 (IFNβ mRNA)a

2’,2’-cGAMP

38.4b

41.9

236

2500b

1200 (ELISA)b

c-di-GMP

52.6d

54.1

1300

4600c

3400 (ELISA)b

CDN Type

a Zhang

et. al. (36), b Gao et. al. (37), c Shu et. al. (31), d Ouyang et. al. (27), e Shang et. al. (30), f Metcalf (130). Cellular assay type provided in
parentheses.
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This finding is consistent with the scientific literature that 2’,3’-cGAMP and 2’,2’-cGAMP
are known agonists.1, 130 Contrastingly, CDG’s docking scores correlated better with
experimental dissociation constants (KD) of STING’s apo form, consistent with the literature that
portrays CDG as a weak STING agonist1 as CDG’s preference to stabilize a more flexible lid
region when bound to hSTING than either 2’,3’-cGAMP or 2’,2’-cGAMP may aid in explaining
why its dissociation constant (KD) is the largest of the three CDNs investigated.130
The study also surmised that flexible docking algorithms (e.g., IFD and MM/GBSA) were
highly correlated to computationally derived dissociation constants (KD) when compared to rigid
docking algorithms (e.g., SP and XP) and may suggest that successful ligand binding is
contingent on induced-fit effects.130 Moreover, since STING is a dimeric protein fully activated in
a closed conformation where a less flexible lid region is formed, hSTING modulation may rely
on the conformational shift of each monomer's lid domain, i.e., “domain swapping,” for robust
signal propagation.130
Aside from potential STING agonism, the apparent structural differences between the
apo and holo forms of hSTING also give credence to a possible conformational target for
antagonizing hSTING, i.e., hSTING’s apo state. A working hypothesis for identifying putative
STING antagonists is not that compounds bind to the open hSTING conformation where initial
interactions within the dimerization region occur, presumably positioning the hSTING monomers
closer together, but also requires the stabilization of a flexible conformation of hSTING’s lid
region for a robust antagonistic response.130
The previously cited research has also demonstrated a high correlation between CDN
control compounds and Schrödinger’s QPLD protocol designed to prioritize ligands that interact
with binding sites composed of complex electrostatics that may polarize ligands when bound to
the target of interest, further substantiated by the presence of highly charged amino acid
residues in the dimerization and lid regions of the hSTING dimer, depending on which STING
isoform is under review.130
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Likewise, the R232H substitution present within the hSTINGREF allele may explain why it
has a diminished cellular response to CDN control compounds1 due to the R232H allele's
deceased electrostatics within its ligand-binding domain. For that reason, the resulting flexibility
of the hSTINGREF allele's lid region may prevent the protein from fully enveloping and tightening
around the bound ligand, thus decreasing the stability of a resulting STING dimer and future
STING oligomer used for downstream signaling.

2.11 Conclusions
Finally, when reviewing the initial consensus docking protocol, the results support the
utility of the constructed agonistic (PDB: 4KSY) and antagonistic (PDB: 4EMU) hSTING models,
respectively130. The third and final chapter will discuss in greater detail how these models can
screen and potentially elucidate the protein conformational preference of monomeric
compounds to either agonize or antagonize hSTING.
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Chapter 3
Investigating Putative STING Modulators

3.1 Discerning a Non-Nucleotide Putative STING Modulator
From previous computational and experimental research130, a low-molecular-weight
organic compound identified as NSC335504, aka clonixeril, was identified as a putative STING
deactivator, binding in a 2:1 stoichiometric relationship.130 NSC335504 is a novel STING
modulator given its structure is not based on a cyclic dinucleotide (CDN). In addition,
NSC335504, aka clonixeril (i.e., the glyceryl ester of clonixin), was proposed as a transdermal
additive to drug delivery formulations for NSAIDs and thus may be a compound of therapeutic
value.135
Remember, this thesis aims to understand STING modulation via a 2:1 stoichiometric
ratio by comparing the binding of putative agonists and antagonists. Furthermore, if a plausible
binding mechanism can be constructed for the NSC335504-STING complex future lead
optimization efforts of NSC335504 could be guided and devised.

3.2 Experimental Plan and Rationale
When investigating the binding mechanism of NSC335504, Figures 2 and 4 necessitate
docking compounds to multiple STING protein conformations (1) due to the structural
differences between the active (closed) and inactive (open) states of hSTING130 and (2) based
on the hypothesized importance induced-fit effects have on potential ligand-hSTING
interactions.130
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As a result, two different hSTING protein conformations are used to assess potential
ligand binding (1) a fully closed hSTING conformation co-crystallized with 2’,3’-cGAMP (PDB
4KSY)36 to simulate hSTING agonism to screen potential agonists and (2) a fully open apo
conformation of hSTING (PDB: 4EMU)31 to simulate hSTING antagonism to screen potential
antagonists.

3.3 Computational Techniques and Strategy
In concert with previously performed molecular modeling130, a site-restricted docking
method summarized in Section 2.7 and a consensus docking approach outlined in Section
2.10 will be implemented.

3.3.1 Protein Preparation of STING Computational Models
Structural coordinates of various hSTING isoforms referenced in Table 2 were
downloaded from the Protein Data Bank (PDB) and prepared with the Protein Preparation
Wizard106 available in the Schrödinger software suite. Any cofactors in the crystal structure used
during the crystallization process (e.g., sulfate and phosphate ions), superfluous protein dimers,
etc., were deleted.130 After removing the crystal artifacts, bond orders were assigned, including
disulfide bridges.130 Original hydrogens were deleted and replaced to reduce substandard
contacts before protonation and hydrogen bonding was optimized.130
Protein-bound waters were retained to aid in discerning protonation states of amino acid
side chains and initial optimization of hydrogen bonds.130 Schrödinger’s Prime113 program was
implemented to add and optimize missing side chains to crystal structures specified in Table 2.
Hydrogen atoms were then added to the protein and any remaining cofactors and any
structural (i.e., protein-bound) waters to employ PROPKA, a program used to predict the
ionization states of proteins at physiological pH (7.4) and optimize hydrogen bonding using the
program ProtAssign.130 After the assignment of hydrogen atoms, each protein model was
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visually inspected at protein-protein interfaces to change protonation states and flip side-chain
residues if and when appropriate.130

3.3.2 Refinement of Computational Models via Molecular Dynamics
MD simulations were then performed on all protein systems in Table 2 with the GPU
accelerated Desmond MD program116, available in the Schrödinger software suite, on two Nvidia
GeForce GTX 1080 Ti video cards.130 In preparing the protein models, a cubic simulation box
was constructed and extended at least 10Å from the protein with imposed periodic boundary
conditions using TIP3P waters as solvent.117 Once TIP3P waters were added, the OPLS3 allatom force field was then applied to all atoms within the simulation box.130
Following the force field application, simulations were run at 310K (body temperature of
humans) and constant pressure of 1 atm.130 Protein systems are then energy minimized with
multiple restrained minimizations to randomize each structure before equilibration and final
simulation.130 Production MD was performed on each STING protein system listed in Table 2 for
250 nanoseconds (ns).130
The asymptotic behavior of the potential energy, radius of gyration (Rg), and root mean
square deviation (RMSD) determined the final equilibration of each hSTING protein model.130
Additional visual inspections of trajectories guided by root mean square fluctuation (RMSF)
profiles for each protein model provided further justification.130

3.3.3 Model Development for Consensus Docking
Once equilibrated, a hierarchical average linkage clustering method based on RMSD
was utilized to determine an average representative structure for each MD simulated hSTING
protein model.130 PROPKA was then reapplied to each equilibrated protein to examine protein
side-chain consistency of amino acid protonation states at physiological pH (7.4).130 The
representative structure was then used for initial modeling with Schrödinger’s GLIDE rigid
receptor docking protocol in the Standard Precision (SP) mode.
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Supplemental molecular docking studies were then conducted using the same
representative protein structure and modeled with three diverse and complementary methods,
Extra Precision (XP) rigid receptor docking, Induced Fit Docking (IFD), and Quantum Polarized
Ligand Docking (QPLD), are discussed in greater detail in Sections 2.5.1-2.5.3. Proper
placement of the receptor grids used in GLIDE’s software program and further analysis of
STING’s LBD of the two computational systems were executed by Schrödinger’s SiteMap
program.51-52, 130, 136
Furthermore, grids were prepared with GLIDE’s receptor grid generation tool119 under
the OPLS3e all-atom force field137. All virtually screened ligands were prepared using
Schrödinger’s Ligprep program138 under the OPLS3e all-atom force field137.

3.3.4 Rigid Receptor Docking
An introduction to rigid docking methods can be found in Section 2.5.1-2.5.1.2 and
Table 4a. Schrödinger’s GLIDE software program was employed to execute virtual screening
campaigns using rigid docking computational methods. In Section 2.5.1, GLIDEScore is
described as a “fitness” scoring function based on ChemScore139-140 that calculates relative
binding free energies to predict the affinity a screened ligand may have for a target by placing a
higher priority on ligands that can better complement the geometries, and chemical properties
present on the GLIDE generated grid of the investigated target.
Different levels of precision are essential when initiating a virtual screening campaign,
and GLIDE can apply both a standard precision (SP) and extra precision (XP) methodology
outlined in Table 4a. The main difference for each method is in differentiating the method’s
overall purpose in molecular modeling. SP docking is used as an ideal first method to screen
compounds of unknown quality to the target of interest and seek to minimize the number of false
negatives (flawed ligands that may be potential binders if optimized) when screening large
compound libraries.67-68
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Table 4a. Rigid Receptor Molecular Modeling Protocols
Modeling
Abbreviation
Goal(s) / Method(s)
Protocol

GLIDE
Standard
Precision

SP

Practical Applications

Ideal for docking ligands of unknown quality

Backbone Rigidity

Ideal to screen extensive ligand databases

Protein-Ligand interactions with negligible
hydrophobic and/or solvent interactions

Seeks to reduce false negatives

Consistent distribution of protein side-chains

References

67-68

Accommodating when the predicted pose has
notable faults
Least computationally expensive protocol

GLIDE
Extra
Precision

XP

Similar to SP docking, however uses a
different energy scoring algorithm and
conformational sampling protocol

Protein environments with significant
hydrophobic contacts

Termed a “harsh” energy scoring formula in
order to refine acceptable ligand poses

Protein enclosures that exhibit involved
hydrogen bonding and/or electrostatic
interactions (e.g. salt bridges)

69

Seeks to reduce false positives
Evaluates based on the “fitness” to model key
interactions of a native ligand-protein complex

Quantum
Polarized

QPLD

An algorithm that endeavors to model ligand
polarizability
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Binding sites with an elevated or ample degree
of charge
73

Ligands that are liable to repolarization upon
binding to the target

Extra precision (XP) docking is primarily used when refinement of a ligand’s “fitness” is
required, as compounds are scored more extensively with increased solvation and hydrophobic
terms incorporated into the XP scoring function to minimize the number of false positives
(ligands that do not bind to a specific conformation of the protein) that may be advanced to later
stages of drug development.
Docking grids used by GLIDE were defined as a rectangular ligand atom inclusion outer
box of 22Å and a ligand centroid constraint inner box of 10Å projected in the x, y, and z
directions. The ligand centroid was defined as the binding site centroid determined by SiteMap.
All SP and XP docking runs were executed with the OPLS3e all-atom force field.137

3.3.5 Induced-Fit Docking
An introduction to the induced-fit docking method can be found in Section 2.5.2 and
Table 4b. Schrödinger’s IFD protocol123 integrates and streamlines the use of Schrödinger’s
GLIDE rigid receptor docking program when considering ligand flexibility and Schrödinger’s
refinement tool Prime to account for protein flexibility. As a reminder, the purpose of the IFD
protocol is to model induced-fit effects as a function of side-chain alternations to a target’s
binding site, induced by ligand binding, to increase relative binding free energy estimations
GLIDE uses to rank screened ligands, as well as, elucidating potential ligand-induced protein
binding modes.
When executing the IFD protocol, separate cubic docking grids are generated for the
hSTING LBD and are centered on the initially docked ligand from the previous XP docking run.
An initial docking run implementing a restrained minimization and a softened vdW potential is
skipped. This is due to IFD’s use of the SP docking protocol in the initial GLIDE docking run
when previous studies suggested XP docking as the preferred docking method.130

54

Table 4b. Flexible Receptor Molecular Modeling Protocols
Modeling
Protocol

Abbreviation

Goal(s) / Method(s)

Practical Applications

Endeavors to model protein flexibility
Induced Fit

Molecular
Mechanics /
Generalized
Born
Surface
Area

IFD

MM/GBSA

Backbone Flexibility

Samples, reintegrates, and energy minimizes Carried out under the presumption that the
a target’s side-chains to assess induced fit
receptor arranges itself to adapt to an inbound
effects
ligand

Endeavors to optimized the relative binding
free energies of a congeneric series of
ligands based on initial protein-ligand
complexes.

70-72

Considered a follow-up to GLIDE docking when
ligands are identified for lead optimization

Uses implicit solvation models and side-chain Beneficial in instances where solvent
sampling for protein flexibility
interactions and protein flexibility are important

55

References

74-84, 111-112

Moreover, the distinct active and inactive protein conformations exhibited by hSTING
and complex hydrophobic and electrostatic interactions within the hSTING LBD support the
exclusive use of the XP-derived ligand pose as the initial ligand conformation for further
analysis.
As a result, the initial XP-derived ligand pose is used to sample the plasticity of the
hSTING LBD by conformationally searching and minimizing binding site amino acid side chain
residues present within 6Å of the ligand. The newly generated low-energy IFD structures within
30 kcal/mol from the best scoring IFD structure are then redocked with the ligand and scored
with GLIDE’s proprietary GLIDEScore function to rank chemically distinct ligands. All IFD
docking runs were executed with the OPLS3e all-atom force field.137

3.3.6 Quantum Polarized Ligand Docking
An introduction to the quantum polarized ligand docking method (QPLD) can be found in
Section 2.5.3 and Table 4b. As a reminder, QPLD is a rigid docking method and, as a result,
does not account for the protein flexibility of the target of interest (TOI). However, it does seek to
consider the effect ligand polarization has upon binding to a target of interest.
As a reminder, quantum mechanics/molecular mechanics (QM/MM) is a hybrid docking
method performed by Schrödinger’s QPLD protocol.129 The procedure seeks to improve the
accuracy of relative binding free energies estimated by GLIDE using molecular mechanics (MM)
defined by the protein and applying a higher level of theory, quantum mechanics (QM), to the
region defined by the ligand to evaluate how charges present on the ligand influence it's binding
to the TOI. When executing the QPLD protocol, the initial XP-derived pose of each screened
ligand is used.
Once defined, QSite128 then calculates the potential ligand polarization induced by the
target’s binding site at the B3LYP/6-31G* level. The MM-derived charges of the ligand are then
pulled, reconstructed with the newly calculated QM charges, docked to the defined receptor
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grid, and saved for further evaluation. All QPLD docking runs were executed with the OPLS3e
all-atom force field.137

3.4 Molecular Docking Results and Discussion
Molecular docking scores for six compounds c-di-GMP, 2’,3’-cGAMP, 2’,2-cGAMP, and
the three zero-order linked dimers of DMXAA, clonixeril, and clonixin (Figures 5-6) were
calculated for two of the four developed hSTING computational models described in Table 2
(4KSY and 4KEMU) and are displayed in Table 5.
Generally speaking, docking correlations in Table 5 support the idea that successful
hSTING docking campaigns may necessitate docking methodologies that incorporate multiple
protein conformations to assess hSTING conformational stability and the preference a potential
binder has for the active or inactive forms of hSTING. In addition, previous molecular
modeling130 established a high correlation with flexible docking methods demonstrating the
importance induced-fit effects have when ligands bind to hSTING, further justified by the fact
that substantial conformational shifts occur between the two hSTING monomeric domains upon
binding a ligand (Figures 2-4).
The importance of induced-fit effects on ligand binding to hSTING is bolstered further
when reviewing the ligand poses generated via the IFD protocol for the compounds screened in
this study (Figures 7-17). The IFD protocol reveals subtle differences between the native
hSTING ligand 2’,3’-cGAMP and other CDNs (2’,2’-cGAMP, and c-di-GMP). The IFD protocol
suggests that 2’,3’-cGAMP’s high affinity to hSTING is due to the cross promoter linkages with
domain swapping lid region residues, especially arginine-238 when docked to both the apo and
holo hSTING conformations (Figures 7-8).

57

Figure 6. 2-D chemical structures of DMXAA, Clonixeril, and Clonixin.
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Table 5. Consensus Docking of Established or Putative Modulators
Compound

PDB

Allele

Form

Ligand

Standard
Deviation

XP

QPLD

IFD

Average

kcal/mol

kcal/mol

kcal/mol

kcal/mol

±

4KSY

R232

Holo

2,3-cGAMP

-10.804

-10.739

-10.588

-10.710

±

0.111

4EMU

R232H

Apo

-

-6.609

-6.565

-7.173

-6.782

±

0.339

4KSY

R232

Holo

2,3-cGAMP

-11.313

-11.060

-11.334

-11.236

±

0.152

4EMU

R232H

Apo

-

-6.483

-7.152

-5.225

-6.287

±

0.978

4KSY

R232

Holo

2,3-cGAMP

-10.084

-11.777

-11.122

-10.994

±

0.854

4EMU

R232H

Apo

-

-6.502

(NSP)

-9.040

-7.771

±

1.795

4KSY

R232

Holo

2,3-cGAMP

-9.319

-9.544

-9.378

-9.414

±

0.117

4EMU

R232H

Apo

-

-11.777

-11.127

-10.108

-11.004

±

0.841

4KSY

R232

Holo

2,3-cGAMP

-7.881

-8.107

-10.987

-8.992

±

1.732

4EMU

R232H

Apo

-

-4.698

-5.434

-6.430

-5.521

±

0.869

4KSY

R232

Holo

2,3-cGAMP

-2.314

-3.742

-2.426

-2.827

±

0.794

4EMU

R232H

Apo

-

-7.037

-7.167

-7.723

-7.309

±

0.364

2’,3’-cGAMP

2’,2’-cGAMP

c-di-GMP

Clonixeril
(LD)

Clonixin
(LD)

DMXAA
(LD)

(LD) - denotes the docking scores for the zero-order bond linked ligand dimer, (NSP) - denotes that no successful pose was generated.
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When bound to the holo-hSTING conformation, 2’,2’-cGAMP (Figure 9), and c-di-GMP
(Figure 10) displace one of the vital arginine-238 residues from the center of the pocket either
inward in the case of 2,2-cGAMP or outward in the case of c-di-GMP. The displacement of
arginine-238 from the center of the binding domain may drive 2’,2’-cGAMP, and c-di-GMP to rely
heavily on their electrostatic interactions with arginine-232 to stabilize the holo conformation of
the hSTING dimer.
In addition, the outward movement of arginine-238 in Figure 10 may present an issue
for c-di-GMP to stabilize the closed conformation as the “domain swapping” that occurs when
hSTING occupies the holo state may cause increased steric strain on c-di-GMP in generating
adverse interactions and clashes between itself and binding site residues that prevent c-di-GMP
from fully closing the hSTING dimer.
When reviewing ligand poses generated by the IFD protocol of the three zero-order
linker dimer compounds of clonixin (Figure 11), DMXAA (Figure 12), and clonixeril (Figure 13),
exciting ligand poses result. The clonixin dimer seems to be able to mimic the cross-promoting
interactions similarly depicted by 2’,3’-cGAMP in Figure 8, which is in contrast with its glycerol
ester analog clonixeril in Figure 13, which does not generate similar interactions of crosspromotion between the two hSTING monomers of the agonist model, even though its relative
binding free energy is within the ± 2 kcal/mol scoring variation when compared to the
corresponding relative binding free energy of clonixin for the identical model. Moreover,
DMXAA’s binding to the holo-hSTING conformation agrees with the known findings outlined in
Section 1.7.4. One DMXAA ligand binds primarily to the bottom of the pocket, propelling the
second DMXAA molecule to interact with residues closer to the lid region illustrated in Figure
12.
Although Figure 12 depicts substantial interactions between two DMXAA monomers and
the holo-hSTING conformation, the relative binding free energy of DMXAA in the agonist model
is substantially lower when comparing it to both hSTING’s native ligand 2’,3’-cGAMP, and
clonixin suggesting that DMXAA is unlikely to bind and potential active hSTING.
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When comparing the ligand poses of 2’,3’-cGAMP, c-di-GMP, and the three zero-order
linked dimer compounds in Figures 7 and 14-17, respectively, when bound to the apo-hSTING
conformation, illustrates the importance of a ligand’s initial binding to hSTING. Figures 7, 16,
and 17 depict the IFD poses of 2’,3’-cGAMP, and the zero-order linked dimers of clonixin and
DMXAA, respectively.
The figures aid in visualizing how initial positioning deep in the binding cleft of the
hSTING ligand-binding domain may allow compounds to interact with residues serine-162,
arginine-238, and threonine-263 and -267 to anchor a potential binder to the bottom of the
pocket where it has the opportunity to maximize the cross-promoting interactions of the
swapped monomeric hSTING domains when closure and organization of hSTING’s lid region
commences.
In contrast, Figures 14 and 15 depict the IFD-generated pose of c-di-GMP and the zeroorder linked dimer of clonixeril when bound to the apo-hSTING conformation, showing that
binding higher in the ligand-binding domain with crucial residues in the lid region conceivably
allowing for the potential stabilization of the open (inactive) conformation of hSTING decreasing
the chance that active hSTING oligomers can form and thus attenuate the downstream signal to
initiate an innate immune response.
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Figure 7. IFD Pose of 2’,3’-cGAMP Docked to 4EMU hSTING model. (A) X-ray structure of c-terminal domain apo-hSTING (R232H) at a
resolution of 1.90 Å. The IFD pose of 2’,3’-cGAMP is depicted in black. (B) Image shows the projected interactions of the IFD pose of 2’,3’cGAMP, ligand defined in black. The grey shading represents the surface of 2’3’-cGAMP.

62

Figure 8. IFD Pose of 2’,3’-cGAMP Docked to 4KSY hSTING model. (A) X-ray structure of c-terminal domain 2’,3’-cGAMP-hSTING (R232) at a
resolution of 1.88 Å. The IFD pose of 2’,3’-cGAMP is depicted in black. The grey shading represents the surface of 2’3’-cGAMP. (B) Image
depicts the projected interactions of the IFD pose of 2’,3’-cGAMP, ligand depicted in black. The grey shading represents the surface of 2’3’cGAMP.
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Figure 9. IFD Pose of 2’,2’-cGAMP Docked to 4KSY hSTING model. (A) The image depicts the projected interactions of the IFD pose of 2’,3’cGAMP, ligand defined in black. The grey shading represents the surface of 2’3’-cGAMP. (B) The image shows the projected interactions of the
IFD pose of 2’,2’-cGAMP, ligand defined in black. The grey shading represents the surface of 2’2’-cGAMP. The green carbon arginine-238 on
monomer A is displaced inward when 2’,2’-cGAMP is bound.
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Figure 10. IFD Pose of c-di-GMP Docked to 4KSY hSTING model. (A) The image depicts the projected interactions of the IFD pose of 2’,3’cGAMP, ligand defined in black. The grey shading represents the surface of 2’3’-cGAMP. (B) The image shows the projected interactions of the
IFD pose of c-di-GMP, ligand defined in black. The grey shading illustrates the surface of c-di-GMP. The red carbon arginine-238 on monomer A
is displaced outward when c-di-GMP is bound.
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Figure 11. IFD Pose of Clonixin Docked to 4KSY hSTING model. (A) The image depicts the projected interactions of the IFD pose of 2’,3’cGAMP, ligand defined in black. The grey shading represents the surface of 2’3’-cGAMP. (B) The image shows the projected interactions of the
IFD pose of the zero-order linked clonixin dimer, ligand defined in black. The grey shading represents the surface of the clonixin dimer.
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Figure 12. IFD Pose of DMXAA Docked to 4KSY hSTING model. (A) The image depicts the projected interactions of the IFD pose of 2’,3’cGAMP, ligand defined in black. The grey shading represents the surface of 2’3’-cGAMP. (B) The image shows the projected interactions of the
IFD pose of the zero-order linked DMXAA dimer, ligand defined in black. The grey shading represents the surface of the DMXAA dimer.
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Figure 13. IFD Pose of Clonixeril Docked to 4KSY hSTING model. (A) The image depicts the projected interactions of the IFD pose of 2’,3’cGAMP, ligand defined in black. The grey shading represents the surface of 2’3’-cGAMP. (B) The image shows the projected interactions of the
IFD pose of the zero-order linked clonixeril dimer, ligand defined in black. The grey shading represents the surface of the clonixeril dimer.
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Figure 14. IFD Pose of c-di-GMP Docked to 4EMU hSTING model. (A) The image depicts the projected interactions of the IFD pose of c-di-GMP
in the 4KSY model, ligand defined in black. The grey shading represents the surface of 2’3’-cGAMP. (B) The image shows the projected
interactions of the IFD pose of c-di-GMP in the 4EMU model, ligand defined in black. The grey shading represents the surface of c-di-GMP.
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Figure 15. IFD Pose of Clonixeril Docked to 4EMU hSTING model. (A) The image depicts the projected interactions of the IFD pose of the zeroorder linked clonixeril dimer in the 4KSY model, ligand defined in black. The grey shading represents the surface of the clonixeril dimer. (B) The
image shows the projected interactions of the IFD pose of the zero-order linked clonixeril dimer, ligand defined in black. The grey shading
represents the surface of the clonixeril dimer.
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Figure 16. IFD Pose of Clonixin Docked to 4EMU hSTING model. (A) The image depicts the projected interactions of the IFD pose of 2’,3’cGAMP, ligand defined in black. The grey shading represents the surface of 2’,3’-cGAMP. (B) The image shows the projected interactions of the
IFD pose of the zero-order linked clonixin dimer, ligand defined in black. The grey shading represents the surface of the clonixin dimer.
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Figure 17. IFD Pose of DMXAA Docked to 4EMU hSTING model. (A) The image depicts the projected interactions of the IFD pose of 2’,3’cGAMP, ligand defined in black. The grey shading represents the surface of 2’,3’-cGAMP. (B) The image shows the projected interactions of the
IFD pose of the zero-order linked DMXAA dimer, ligand defined in black. The grey shading represents the surface of the DMXAA dimer.
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3.5 Conclusions
3.5.1 Distinguishing STING Modulation via Ligand Binding
After reviewing all docked poses in chapter 3, modulation of hSTING seems dynamic.
Structural changes from the initial inactive conformation to a final active conformation leave an
immense range of binding affinities a potential ligand can generate to induce either an agonistic
or antagonistic response, a challenging prospect to explore experimentally.
However, the computational approach outlined above provides a simple method to
screen ligands to hSTING, whether they are monomeric or dimeric in nature. Moreover,
screening compounds to different conformations of hSTING provide investigators with additional
awareness of a potential binder's capabilities in modulating hSTING. The development of either
an hSTING agonist or antagonist will require future researchers to develop compounds that
seek to decrease the flexibility of the initial hSTING dimer, whether or not the lid region is
closed.
Furthermore, successful agonism or antagonism of hSTING will be contingent on a
ligand’s ability to clasp the two hSTING monomers together, decreasing its initial flexibility long
enough for other hSTING dimers to oligomerize, a fact that may be vital for both the closed and
open hSTING conformations.

3.5.2 Thoughts on a Lead Optimization Strategy
Finally, when reviewing the ligand poses of both clonixeril and clonixin, it could be
suggested that both have the potential to bind and modulate hSTING. However, these ligands
do not come without challenges. Clonixin may be a potential agonist given the dimeric pose
generated from the hSTINGWT agonist model. Although, clonixin is small, making the dimer less
adept at binding, clasping, and tightening the hSTING protein. ADME issues should also be
considered given that clonixin contains a carboxylic acid, a functional advantage when clonixin
is bound to the fully active conformation of hSTING as carboxylic acids can provide numerous
electrostatic interactions between the negatively charged carboxylic acid present on clonixin and
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the positively charged arginines at positions 232 and 238 (within the lid region) of each
hSTINGWT monomer. However, the charged nature of clonixin’s carboxylic acid may be
counterproductive for membrane permeability as hSTING exists as an ER membrane-bound
protein within the cytosol of a human cell. Additionally, clonixeril shows potential in binding
hSTING as an antagonist, given how clonixeril interacts with the open hSTINGREF antagonist
model. However, the highly rotatable glycerol ester tail on clonxeril may equip each ligand
monomer with ample flexibility when bound, decreasing the potential for a clonixeril zero-order
dimer to stabilize hSTING without lid closure and thus may hinder an antagonistic response.
In the future, researchers will first need to consider the hSTING conformation they intend
to target when developing future dimers by incorporating aspects where a ligand can flex but
maintain its overall shape. For potential agonists, creating a cyclized form of a potential ligand
may be more advantageous as the form may allow the putative dimer to bind deep in the cleft of
the pocket and maximize the cross-promoting interactions the swapped domains generate when
hSTING is in its fully active conformation.
In contrast, a linearized form of an identical ligand may serve as a better putative
antagonist by providing the proposed dimer a scaffold to interact with both the dimerization and
lid regions of hSTING simultaneously, thus closing but not ordering the hSTING lid region in a
way that allows hSTING oligomers to form.

3.6 Future Research Studies
In conclusion, as this chapter discussed, the site-restricted docking approach described
in this study seems viable. Further progress in developing either an hSTING agonist or
antagonist will depend on how a core scaffold, either clonixeril or clonxin, is linked and
optimized.
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